{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T16:24:49Z","timestamp":1795019089849,"version":"4.10.1"},"reference-count":192,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1038\/s41574-023-00886-5","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T08:02:32Z","timestamp":1693900952000},"page":"722-740","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":422,"title":["Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0618-6147","authenticated-orcid":false,"given":"Stephan","family":"Petersenn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-6289","authenticated-orcid":false,"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe F.","family":"Casanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giustina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5817-3594","authenticated-orcid":false,"given":"Nienke","family":"Biermasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly M. K.","family":"Biller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Bronstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Chanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9255-653X","authenticated-orcid":false,"given":"Hidenori","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Gadelha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-488X","authenticated-orcid":false,"given":"Yona","family":"Greenman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gurnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2508-9588","authenticated-orcid":false,"given":"Ken K. Y.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Honegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana G.","family":"Ioachimescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula B.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4696-0643","authenticated-orcid":false,"given":"Niki","family":"Karavitaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Katznelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Lodish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0918-637X","authenticated-orcid":false,"given":"Dominique","family":"Maiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani J.","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Molitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Muir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Neggers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1194-9866","authenticated-orcid":false,"given":"Alberto M.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9632-1348","authenticated-orcid":false,"given":"Rosario","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalmon","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9517-338X","authenticated-orcid":false,"given":"Gerald","family":"Raverot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6495-2244","authenticated-orcid":false,"given":"Roberto","family":"Salvatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Shimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Spencer-Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1918-1959","authenticated-orcid":false,"given":"Greisa","family":"Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Wass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2355-3447","authenticated-orcid":false,"given":"Shlomo","family":"Melmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"886_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","volume":"65","author":"FF Casanueva","year":"2006","unstructured":"Casanueva, F. F. et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. 65, 265\u2013273 (2006).","journal-title":"Clin. Endocrinol."},{"key":"886_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed, S. et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 273\u2013288 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR3","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s11596-022-2673-6","volume":"42","author":"XY Wan","year":"2022","unstructured":"Wan, X. Y. et al. Overview of the 2022 WHO classification of pituitary adenomas\/pituitary neuroendocrine tumors: clinical practices, controversies, and perspectives. Curr. Med. Sci. 42, 1111\u20131118 (2022).","journal-title":"Curr. Med. Sci."},{"key":"886_CR4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1210\/jc.2018-01071","volume":"104","author":"CE Stiles","year":"2018","unstructured":"Stiles, C. E., Tetteh-Wayoe, E. T., Bestwick, J., Steeds, R. P. & Drake, W. M. A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with cabergoline. J. Clin. Endocrinol. Metab. 104, 523\u2013538 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR5","doi-asserted-by":"publisher","first-page":"dgaa652","DOI":"10.1210\/clinem\/dgaa652","volume":"105","author":"C Hage","year":"2020","unstructured":"Hage, C. & Salvatori, R. Predictors of the response to dopaminergic therapy in patients with prolactinoma. J. Clin. Endocrinol. Metab. 105, dgaa652 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1055\/a-1247-4908","volume":"129","author":"S Giese","year":"2021","unstructured":"Giese, S., Nasi-Kordhishti, I. & Honegger, J. Outcomes of transsphenoidal microsurgery for prolactinomas \u2013 a contemporary series of 162 cases. Exp. Clin. Endocrinol. Diabetes 129, 163\u2013171 (2021).","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"886_CR7","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1007\/s11102-021-01188-7","volume":"24","author":"KJ Yagnik","year":"2021","unstructured":"Yagnik, K. J. et al. Surgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis. Pituitary 24, 978\u2013988 (2021).","journal-title":"Pituitary"},{"key":"886_CR8","doi-asserted-by":"publisher","first-page":"9930059","DOI":"10.1155\/2021\/9930059","volume":"2021","author":"J Lu","year":"2021","unstructured":"Lu, J. et al. Surgery and medical treatment in microprolactinoma: a systematic review and meta-analysis. Int. J. Endocrinol. 2021, 9930059 (2021).","journal-title":"Int. J. Endocrinol."},{"key":"886_CR9","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1210\/clinem\/dgz144","volume":"105","author":"AH Zamanipoor Najafabadi","year":"2020","unstructured":"Zamanipoor Najafabadi, A. H. et al. Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 105, e32\u2013e41 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11102-019-01010-5","volume":"23","author":"A Glezer","year":"2020","unstructured":"Glezer, A. & Bronstein, M. D. Prolactinomas in pregnancy: considerations before conception and during pregnancy. Pituitary 23, 65\u201369 (2020).","journal-title":"Pituitary"},{"key":"886_CR11","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-21-0462","volume":"185","author":"A Luger","year":"2021","unstructured":"Luger, A. et al. ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. Eur. J. Endocrinol. 185, G1\u2013G33 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR12","doi-asserted-by":"publisher","first-page":"R205","DOI":"10.1530\/EJE-14-0848","volume":"172","author":"ME Molitch","year":"2015","unstructured":"Molitch, M. E. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur. J. Endocrinol. 172, R205\u2013R213 (2015).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s11102-020-01041-3","volume":"23","author":"L di Filippo","year":"2020","unstructured":"di Filippo, L., Doga, M., Resmini, E. & Giustina, A. Hyperprolactinemia and bone. Pituitary 23, 314\u2013321 (2020).","journal-title":"Pituitary"},{"key":"886_CR14","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1530\/EJE-22-0440","volume":"187","author":"P Burman","year":"2022","unstructured":"Burman, P. et al. Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur. J. Endocrinol. 187, 593\u2013605 (2022).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt, G. H. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br. Med. J. 336, 924\u2013926 (2008).","journal-title":"Br. Med. J."},{"key":"886_CR16","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1210\/jc.2007-1907","volume":"93","author":"BA Swiglo","year":"2008","unstructured":"Swiglo, B. A. et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J. Clin. Endocrinol. Metab. 93, 666\u2013673 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu, M. et al. Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol. 9, 847\u2013875 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"886_CR18","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","volume":"33","author":"P Chanson","year":"2019","unstructured":"Chanson, P. & Maiter, D. The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best. Pract. Res. Clin. Endocrinol. Metab. 33, 101290 (2019).","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"886_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000495184","volume":"109","author":"I Shimon","year":"2019","unstructured":"Shimon, I. Giant prolactinomas. Neuroendocrinology 109, 51\u201356 (2019).","journal-title":"Neuroendocrinology"},{"key":"886_CR20","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1210\/jcem-71-6-1427","volume":"71","author":"V Herman","year":"1990","unstructured":"Herman, V., Fagin, J., Gonsky, R., Kovacs, K. & Melmed, S. Clonal origin of pituitary adenomas. J. Clin. Endocrinol. Metab. 71, 1427\u20131433 (1990).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR21","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1056\/NEJMra1810772","volume":"382","author":"S Melmed","year":"2020","unstructured":"Melmed, S. Pituitary-tumor endocrinopathies. N. Engl. J. Med. 382, 937\u2013950 (2020).","journal-title":"N. Engl. J. Med."},{"key":"886_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16052-8","volume":"11","author":"C Li","year":"2020","unstructured":"Li, C. et al. Somatic SF3B1 hotspot mutation in prolactinomas. Nat. Commun. 11, 2506 (2020).","journal-title":"Nat. Commun."},{"key":"886_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1210\/endrev\/bnaa031","volume":"42","author":"ML Brandi","year":"2021","unstructured":"Brandi, M. L. et al. Multiple endocrine neoplasia type 1: latest insights. Endocr. Rev. 42, 133\u2013170 (2021).","journal-title":"Endocr. Rev."},{"key":"886_CR24","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1210\/jc.2014-3670","volume":"100","author":"S Salenave","year":"2015","unstructured":"Salenave, S. et al. Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J. Clin. Endocrinol. Metab. 100, 1177\u20131186 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR25","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1530\/EJE-21-0630","volume":"185","author":"M Le Bras","year":"2021","unstructured":"Le Bras, M. et al. Pituitary adenoma in patients with multiple endocrine neoplasia type 1: a cohort study. Eur. J. Endocrinol. 185, 863\u2013873 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR26","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1172\/JCI63937","volume":"122","author":"C Sonigo","year":"2012","unstructured":"Sonigo, C. et al. Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. J. Clin. Invest. 122, 3791\u20133795 (2012).","journal-title":"J. Clin. Invest."},{"key":"886_CR27","doi-asserted-by":"publisher","first-page":"8217","DOI":"10.3390\/ijms22158217","volume":"22","author":"TM Barber","year":"2021","unstructured":"Barber, T. M. et al. Mechanisms of central hypogonadism. Int. J. Mol. Sci. 22, 8217 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"886_CR28","doi-asserted-by":"publisher","first-page":"e4551","DOI":"10.1210\/clinem\/dgaa650","volume":"105","author":"M Sehemby","year":"2020","unstructured":"Sehemby, M. et al. Predictors of chronic LH-testosterone axis suppression in male macroprolactinomas with normoprolactinemia on cabergoline. J. Clin. Endocrinol. Metab. 105, e4551\u2013e4557 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR29","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s11102-022-01259-3","volume":"25","author":"Y Rudman","year":"2022","unstructured":"Rudman, Y., Duskin-Bitan, H., Masri-Iraqi, H., Akirov, A. & Shimon, I. Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma. Pituitary 25, 882\u2013890 (2022).","journal-title":"Pituitary"},{"key":"886_CR30","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jama.2016.19699","volume":"317","author":"ME Molitch","year":"2017","unstructured":"Molitch, M. E. Diagnosis and treatment of pituitary adenomas: a review. J. Am. Med. Assoc. 317, 516\u2013524 (2017).","journal-title":"J. Am. Med. Assoc."},{"key":"886_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3109\/07435800.2015.1135444","volume":"41","author":"B Peric","year":"2016","unstructured":"Peric, B. et al. Obesity and hypercholesterolemia in patients with prolactinomas: could DHEA-S and growth hormone be the missing link? Endocr. Res. 41, 200\u2013206 (2016).","journal-title":"Endocr. Res."},{"key":"886_CR32","first-page":"3053","volume":"85","author":"JJ Pinzone","year":"2000","unstructured":"Pinzone, J. J. et al. Primary medical therapy of micro- and macroprolactinomas in men. J. Clin. Endocrinol. Metab. 85, 3053\u20133057 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR33","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1055\/a-0752-0741","volume":"50","author":"P Iglesias","year":"2018","unstructured":"Iglesias, P. et al. Giant prolactinoma in men: clinical features and therapeutic outcomes. Horm. Metab. Res. 50, 791\u2013796 (2018).","journal-title":"Horm. Metab. Res."},{"key":"886_CR34","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1210\/jc.2003-030979","volume":"89","author":"A Colao","year":"2004","unstructured":"Colao, A. et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J. Clin. Endocrinol. Metab. 89, 1704\u20131711 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR35","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11102-014-0563-z","volume":"18","author":"A Tirosh","year":"2015","unstructured":"Tirosh, A., Benbassat, C., Lifshitz, A. & Shimon, I. Hypopituitarism patterns and prevalence among men with macroprolactinomas. Pituitary 18, 108\u2013115 (2015).","journal-title":"Pituitary"},{"key":"886_CR36","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1210\/jc.2016-2118","volume":"101","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu, M. et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 3888\u20133921 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR37","doi-asserted-by":"publisher","first-page":"E2203","DOI":"10.3390\/jcm8122203","volume":"8","author":"I Samperi","year":"2019","unstructured":"Samperi, I., Lithgow, K. & Karavitaki, N. Hyperprolactinaemia. J. Clin. Med. 8, E2203 (2019).","journal-title":"J. Clin. Med."},{"key":"886_CR38","unstructured":"Kaiser, U. & Ho, K. Pituitary physiology and diagnostic evaluation. In Williams Textbook of Endocrinology (eds Melmed, S., Koenig, R., Rosen, C. J., Auchus, R. J. & Goldfine, A, B.) 184\u2013235 (Elsevier, 2019)."},{"key":"886_CR39","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1365-2265.2006.02627.x","volume":"65","author":"N Karavitaki","year":"2006","unstructured":"Karavitaki, N. et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin. Endocrinol. 65, 524\u2013529 (2006).","journal-title":"Clin. Endocrinol."},{"key":"886_CR40","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s12020-021-02701-5","volume":"73","author":"O Alexopoulou","year":"2021","unstructured":"Alexopoulou, O. et al. Outcome of pituitary hormone deficits after surgical treatment of nonfunctioning pituitary macroadenomas. Endocrine 73, 166\u2013176 (2021).","journal-title":"Endocrine"},{"key":"886_CR41","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1007\/s11102-017-0833-7","volume":"20","author":"SMC De Sousa","year":"2017","unstructured":"De Sousa, S. M. C. et al. Vasculogenic hyperprolactinemia: severe prolactin excess in association with internal carotid artery aneurysms. Pituitary 20, 676\u2013682 (2017).","journal-title":"Pituitary"},{"key":"886_CR42","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3171\/2019.3.JNS19121","volume":"133","author":"WT Burke","year":"2019","unstructured":"Burke, W. T. et al. Prolactinomas and nonfunctioning adenomas: preoperative diagnosis of tumor type using serum prolactin and tumor size. J. Neurosurg. 133, 321\u2013328 (2019).","journal-title":"J. Neurosurg."},{"key":"886_CR43","doi-asserted-by":"publisher","first-page":"e1402","DOI":"10.1210\/clinem\/dgab868","volume":"107","author":"DJ Cote","year":"2022","unstructured":"Cote, D. J. et al. Oral contraceptive and menopausal hormone therapy use and risk of pituitary adenoma: cohort and case-control analyses. J. Clin. Endocrinol. Metab. 107, e1402\u2013e1412 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR44","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3171\/2014.9.JNS132687","volume":"122","author":"WI Schievink","year":"2015","unstructured":"Schievink, W. I. et al. Hyperprolactinemia due to spontaneous intracranial hypotension. J. Neurosurg. 122, 1020\u20131025 (2015).","journal-title":"J. Neurosurg."},{"key":"886_CR45","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.4158\/EP-2020-0260","volume":"26","author":"A Tsur","year":"2020","unstructured":"Tsur, A., Dreyfuss, E., Ness-Abramof, R., Pollack, R. & Cahn, A. Role of cannulated prolactin test in evaluation of hyperprolactinemia \u2013 a retrospective study. Endocr. Pract. 26, 1304\u20131311 (2020).","journal-title":"Endocr. Pract."},{"key":"886_CR46","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11102-014-0576-7","volume":"18","author":"MB Whyte","year":"2015","unstructured":"Whyte, M. B. et al. Importance of cannulated prolactin test in the definition of hyperprolactinaemia. Pituitary 18, 319\u2013325 (2015).","journal-title":"Pituitary"},{"key":"886_CR47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.alcohol.2006.03.006","volume":"38","author":"JA Mennella","year":"2006","unstructured":"Mennella, J. A. & Pepino, M. Y. Short-term effects of alcohol consumption on the hormonal milieu and mood states in nulliparous women. Alcohol 38, 29\u201336 (2006).","journal-title":"Alcohol"},{"key":"886_CR48","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11102-019-01024-z","volume":"23","author":"S Petersenn","year":"2020","unstructured":"Petersenn, S. Biochemical diagnosis in prolactinomas: some caveats. Pituitary 23, 9\u201315 (2020).","journal-title":"Pituitary"},{"key":"886_CR49","doi-asserted-by":"publisher","first-page":"117955811987192","DOI":"10.1177\/1179558119871921","volume":"13","author":"C Delcour","year":"2019","unstructured":"Delcour, C., Robin, G., Young, J. & Dewailly, D. PCOS and hyperprolactinemia: what do we know in 2019? Clin. Med. Insights Reprod. Health 13, 1179558119871921 (2019).","journal-title":"Clin. Med. Insights Reprod. Health"},{"key":"886_CR50","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1210\/jc.2015-2152","volume":"100","author":"J Honegger","year":"2015","unstructured":"Honegger, J. et al. Diagnosis of primary hypophysitis in Germany. J. Clin. Endocrinol. Metab. 100, 3841\u20133849 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR51","doi-asserted-by":"publisher","first-page":"101324","DOI":"10.1016\/j.beem.2019.101324","volume":"33","author":"VV Borba","year":"2019","unstructured":"Borba, V. V., Zandman-Goddard, G. & Shoenfeld, Y. Prolactin and autoimmunity: the hormone as an inflammatory cytokine. Best. Pract. Res. Clin. Endocrinol. Metab. 33, 101324 (2019).","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"886_CR52","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu, M., Langlois, F., Lim, D. S. T., Varlamov, E. V. & Melmed, S. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 10, 804\u2013826 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"886_CR53","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/clinem\/dgz022","volume":"105","author":"F de Vries","year":"2020","unstructured":"de Vries, F. et al. Opioids and their endocrine effects: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 105, 1020\u20131029 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR54","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11102-008-0106-6","volume":"11","author":"ME Molitch","year":"2008","unstructured":"Molitch, M. E. Drugs and prolactin. Pituitary 11, 209\u2013218 (2008).","journal-title":"Pituitary"},{"key":"886_CR55","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.schres.2021.08.013","volume":"237","author":"Y Zhu","year":"2021","unstructured":"Zhu, Y. et al. Prolactin levels influenced by antipsychotic drugs in schizophrenia: a systematic review and network meta-analysis. Schizophr. Res. 237, 20\u201325 (2021).","journal-title":"Schizophr. Res."},{"key":"886_CR56","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/s12020-020-02497-w","volume":"72","author":"L Aliberti","year":"2021","unstructured":"Aliberti, L. et al. Hypeprolactinemia: still an insidious diagnosis. Endocrine 72, 928\u2013931 (2021).","journal-title":"Endocrine"},{"key":"886_CR57","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1515\/cclm-2016-0902","volume":"55","author":"M Overgaard","year":"2017","unstructured":"Overgaard, M. & Pedersen, S. M. Serum prolactin revisited: parametric reference intervals and cross platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia. Clin. Chem. Lab. Med. 55, 1744\u20131753 (2017).","journal-title":"Clin. Chem. Lab. Med."},{"key":"886_CR58","first-page":"3","volume":"39","author":"M Saleem","year":"2018","unstructured":"Saleem, M., Martin, H. & Coates, P. Prolactin biology and laboratory measurement: an update on physiology and current analytical issues. Clin. Biochem. Rev. 39, 3\u201316 (2018).","journal-title":"Clin. Biochem. Rev."},{"key":"886_CR59","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1210\/jc.2010-0114","volume":"95","author":"IR Wallace","year":"2010","unstructured":"Wallace, I. R. et al. Ten-year clinical follow-up of a cohort of 51 patients with macroprolactinemia establishes it as a benign variant. J. Clin. Endocrinol. Metab. 95, 3268\u20133271 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR60","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1046\/j.1365-2265.1999.00757.x","volume":"51","author":"AO Olukoga","year":"1999","unstructured":"Olukoga, A. O. & Kane, J. W. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin. Endocrinol. 51, 119\u2013126 (1999).","journal-title":"Clin. Endocrinol."},{"key":"886_CR61","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s11102-022-01246-8","volume":"25","author":"V Raverot","year":"2022","unstructured":"Raverot, V. et al. Prolactin immunoassay: does the high-dose hook effect still exist? Pituitary 25, 653\u2013657 (2022).","journal-title":"Pituitary"},{"key":"886_CR62","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11102-018-0924-0","volume":"22","author":"LB Nachtigall","year":"2019","unstructured":"Nachtigall, L. B. et al. Physicians\u2019 awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a \u201cPituitary Society\u201d survey. Pituitary 22, 37\u201345 (2019).","journal-title":"Pituitary"},{"key":"886_CR63","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3390\/diagnostics12081816","volume":"12","author":"S Gallo-Bernal","year":"2022","unstructured":"Gallo-Bernal, S. et al. Nephrogenic systemic fibrosis in patients with chronic kidney disease after the use of gadolinium-based contrast agents: a review for the cardiovascular imager. Diagnostics 12, 1816 (2022).","journal-title":"Diagnostics"},{"key":"886_CR64","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11102-013-0473-5","volume":"17","author":"AG Alkabbani","year":"2014","unstructured":"Alkabbani, A. G. et al. Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth? Pituitary 17, 97\u2013102 (2014).","journal-title":"Pituitary"},{"key":"886_CR65","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11102-019-01001-6","volume":"23","author":"EV Varlamov","year":"2020","unstructured":"Varlamov, E. V., Hinojosa-Amaya, J. M. & Fleseriu, M. Magnetic resonance imaging in the management of prolactinomas; a review of the evidence. Pituitary 23, 16\u201326 (2020).","journal-title":"Pituitary"},{"key":"886_CR66","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1055\/s-0034-1389925","volume":"46","author":"M Lombardi","year":"2014","unstructured":"Lombardi, M. et al. Lower prolactin levels during cabergoline treatment are associated to tumor shrinkage in prolactin secreting pituitary adenoma. Horm. Metab. Res. 46, 939\u2013942 (2014).","journal-title":"Horm. Metab. Res."},{"key":"886_CR67","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1210\/jcem-68-2-412","volume":"68","author":"J Schlechte","year":"1989","unstructured":"Schlechte, J., Dolan, K., Sherman, B., Chapler, F. & Luciano, A. The natural history of untreated hyperprolactinemia: a prospective analysis. J. Clin. Endocrinol. Metab. 68, 412\u2013418 (1989).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR68","doi-asserted-by":"crossref","unstructured":"Hinojosa-Amaya, J. M., Varlamov, E. V., McCartney, S. & Fleseriu, M. Pituitary magnetic resonance imaging use in the posttreatment follow-up of secreting pituitary adenomas. In Pituitary Tumors: A Comprehensive and Interdisciplinary Approach (eds J. Honegger, J., Reincke, M. & Petersenn, S.) 447\u2013455 (Academic Press, 2021).","DOI":"10.1016\/B978-0-12-819949-7.00013-5"},{"key":"886_CR69","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00234-015-1519-3","volume":"57","author":"J Kreutz","year":"2015","unstructured":"Kreutz, J. et al. Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference. Neuroradiology 57, 679\u2013684 (2015).","journal-title":"Neuroradiology"},{"key":"886_CR70","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s12020-018-1765-3","volume":"63","author":"MC Burlacu","year":"2019","unstructured":"Burlacu, M. C., Maiter, D., Duprez, T. & Delgrange, E. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists. Endocrine 63, 323\u2013331 (2019).","journal-title":"Endocrine"},{"key":"886_CR71","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11102-018-0877-3","volume":"21","author":"SC Dogansen","year":"2018","unstructured":"Dogansen, S. C. et al. Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas. Pituitary 21, 347\u2013354 (2018).","journal-title":"Pituitary"},{"key":"886_CR72","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1530\/EJE-21-0561","volume":"185","author":"B Biagetti","year":"2021","unstructured":"Biagetti, B. et al. Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline. Eur. J. Endocrinol. 185, 587\u2013595 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR73","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1530\/EJE-16-0897","volume":"176","author":"J Eroukhmanoff","year":"2017","unstructured":"Eroukhmanoff, J. et al. MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment. Eur. J. Endocrinol. 176, 323\u2013328 (2017).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR74","doi-asserted-by":"publisher","first-page":"e686","DOI":"10.1016\/j.wneu.2019.05.249","volume":"129","author":"OO Akinduro","year":"2019","unstructured":"Akinduro, O. O. et al. Radiographic and hormonal regression in prolactinomas: an analysis of treatment failure. World Neurosurg. 129, e686\u2013e694 (2019).","journal-title":"World Neurosurg."},{"key":"886_CR75","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1210\/jc.2008-2103","volume":"94","author":"J Kharlip","year":"2009","unstructured":"Kharlip, J., Salvatori, R., Yenokyan, G. & Wand, G. S. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J. Clin. Endocrinol. Metab. 94, 2428\u20132436 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR76","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s12020-017-1444-9","volume":"59","author":"MY Xia","year":"2018","unstructured":"Xia, M. Y., Lou, X. H., Lin, S. J. & Wu, Z. B. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine 59, 50\u201361 (2018).","journal-title":"Endocrine"},{"key":"886_CR77","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","volume":"43","author":"S Melmed","year":"2022","unstructured":"Melmed, S. et al. Clinical biology of the pituitary adenoma. Endocr. Rev. 43, 1003\u20131037 (2022).","journal-title":"Endocr. Rev."},{"key":"886_CR78","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1530\/EJE-21-0145","volume":"185","author":"E Kuhn","year":"2021","unstructured":"Kuhn, E., Weinreich, A. A., Biermasz, N. R., Jorgensen, J. O. L. & Chanson, P. Apoplexy of microprolactinomas during pregnancy: report of five cases and review of the literature. Eur. J. Endocrinol. 185, 99\u2013108 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR79","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11102-019-01016-z","volume":"23","author":"J Honegger","year":"2019","unstructured":"Honegger, J., Nasi-Kordhishti, I., Aboutaha, N. & Giese, S. Surgery for prolactinomas \u2013 a better choice? Pituitary 23, 45\u201351 (2019).","journal-title":"Pituitary"},{"key":"886_CR80","doi-asserted-by":"publisher","first-page":"101278","DOI":"10.1016\/j.beem.2019.05.002","volume":"33","author":"WA Bashari","year":"2019","unstructured":"Bashari, W. A. et al. Modern imaging of pituitary adenomas. Best. Pract. Res. Clin. Endocrinol. Metab. 33, 101278 (2019).","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"886_CR81","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s11102-022-01229-9","volume":"25","author":"WA Bashari","year":"2022","unstructured":"Bashari, W. A. et al. 11C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy. Pituitary 25, 573\u2013586 (2022).","journal-title":"Pituitary"},{"key":"886_CR82","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s11102-022-01230-2","volume":"25","author":"LEH Bakker","year":"2022","unstructured":"Bakker, L. E. H. et al. Implementation of functional imaging using 11C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery. Pituitary 25, 587\u2013601 (2022).","journal-title":"Pituitary"},{"key":"886_CR83","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1210\/jcem-64-2-391","volume":"64","author":"JC Prior","year":"1987","unstructured":"Prior, J. C., Cox, T. A., Fairholm, D., Kostashuk, E. & Nugent, R. Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen. J. Clin. Endocrinol. Metab. 64, 391\u2013394 (1987).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR84","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3390\/jcm12041437","volume":"12","author":"A Akirov","year":"2023","unstructured":"Akirov, A. & Rudman, Y. The role of aromatase inhibitors in male prolactinoma. J. Clin. Med. 12, 1437 (2023).","journal-title":"J. Clin. Med."},{"key":"886_CR85","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1210\/jc.2009-0739","volume":"94","author":"SA Burnett-Bowie","year":"2009","unstructured":"Burnett-Bowie, S. A., McKay, E. A., Lee, H. & Leder, B. Z. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J. Clin. Endocrinol. Metab. 94, 4785\u20134792 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR86","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1530\/EJE-09-0084","volume":"161","author":"RS Ribeiro","year":"2009","unstructured":"Ribeiro, R. S. & Abucham, J. Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment. Eur. J. Endocrinol. 161, 163\u2013169 (2009).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR87","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ando.2012.03.040","volume":"73","author":"S Salenave","year":"2012","unstructured":"Salenave, S., Trabado, S., Maione, L., Brailly-Tabard, S. & Young, J. Male acquired hypogonadotropic hypogonadism: diagnosis and treatment. Ann. Endocrinol. 73, 141\u2013146 (2012).","journal-title":"Ann. Endocrinol."},{"key":"886_CR88","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1026232124988","volume":"6","author":"A Drincic","year":"2003","unstructured":"Drincic, A. et al. Men with acquired hypogonadotropic hypogonadism treated with testosterone may be fertile. Pituitary 6, 5\u201310 (2003).","journal-title":"Pituitary"},{"key":"886_CR89","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ecl.2007.10.013","volume":"37","author":"T Mancini","year":"2008","unstructured":"Mancini, T., Casanueva, F. F. & Giustina, A. Hyperprolactinemia and prolactinomas. Endocrinol. Metab. Clin. North Am. 37, 67\u201399 (2008).","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"886_CR90","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s11102-011-0293-4","volume":"14","author":"G Mazziotti","year":"2011","unstructured":"Mazziotti, G. et al. High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary 14, 299\u2013306 (2011).","journal-title":"Pituitary"},{"key":"886_CR91","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ecl.2020.05.006","volume":"49","author":"EA Giraldi","year":"2020","unstructured":"Giraldi, E. A. & Ioachimescu, A. G. The role of dopamine agonists in pituitary adenomas. Endocrinol. Metab. Clin. North Am. 49, 453\u2013474 (2020).","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"886_CR92","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/cen.12242","volume":"79","author":"AB Moraes","year":"2013","unstructured":"Moraes, A. B., Silva, C. M., Vieira Neto, L. & Gadelha, M. R. Giant prolactinomas: the therapeutic approach. Clin. Endocrinol. 79, 447\u2013456 (2013).","journal-title":"Clin. Endocrinol."},{"key":"886_CR93","doi-asserted-by":"publisher","first-page":"R213","DOI":"10.1530\/EJE-14-0013","volume":"170","author":"D Maiter","year":"2014","unstructured":"Maiter, D. & Delgrange, E. Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur. J. Endocrinol. 170, R213\u2013R227 (2014).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR94","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s11011-018-0217-3","volume":"33","author":"HY Huang","year":"2018","unstructured":"Huang, H. Y., Lin, S. J., Zhao, W. G. & Wu, Z. B. Cabergoline versus bromocriptine for the treatment of giant prolactinomas: a quantitative and systematic review. Metab. Brain Dis. 33, 969\u2013976 (2018).","journal-title":"Metab. Brain Dis."},{"key":"886_CR95","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3803\/EnM.2014.29.3.280","volume":"29","author":"Y Lee","year":"2014","unstructured":"Lee, Y. et al. Early prediction of long-term response to cabergoline in patients with macroprolactinomas. Endocrinol. Metab. 29, 280\u2013292 (2014).","journal-title":"Endocrinol. Metab."},{"key":"886_CR96","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.4158\/EP15804.OR","volume":"21","author":"A Tirosh","year":"2015","unstructured":"Tirosh, A., Benbassat, C. & Shimon, I. Short-term decline in prolactin concentrations can predict future prolactin normalization, tumor shrinkage, and time to remission in men with macroprolactinomas. Endocr. Pract. 21, 1240\u20131247 (2015).","journal-title":"Endocr. Pract."},{"key":"886_CR97","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1023\/B:PITU.0000004798.27230.ed","volume":"6","author":"MD Johnson","year":"2003","unstructured":"Johnson, M. D., Woodburn, C. J. & Vance, M. L. Quality of life in patients with a pituitary adenoma. Pituitary 6, 81\u201387 (2003).","journal-title":"Pituitary"},{"key":"886_CR98","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11102-019-01009-y","volume":"23","author":"H Duskin-Bitan","year":"2020","unstructured":"Duskin-Bitan, H. & Shimon, I. Prolactinomas in males: any differences? Pituitary 23, 52\u201357 (2020).","journal-title":"Pituitary"},{"key":"886_CR99","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11102-023-01313-8","volume":"26","author":"MAM Stumpf","year":"2023","unstructured":"Stumpf, M. A. M. et al. How to manage intolerance to dopamine agonist in patients with prolactinoma. Pituitary 26, 187\u2013196 (2023).","journal-title":"Pituitary"},{"key":"886_CR100","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1210\/clinem\/dgz076","volume":"105","author":"SMC De Sousa","year":"2020","unstructured":"De Sousa, S. M. C. et al. Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. J. Clin. Endocrinol. Metab. 105, e108\u2013e118 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR101","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1530\/EJE-18-0682","volume":"180","author":"AG Ioachimescu","year":"2019","unstructured":"Ioachimescu, A. G., Fleseriu, M., Hoffman, A. R., Vaughan Iii, T. B. & Katznelson, L. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur. J. Endocrinol. 180, 31\u201340 (2019).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR102","doi-asserted-by":"publisher","first-page":"579606","DOI":"10.3389\/fendo.2020.579606","volume":"11","author":"JM Hinojosa-Amaya","year":"2020","unstructured":"Hinojosa-Amaya, J. M. et al. Depression and impulsivity self-assessment tools to identify dopamine agonist side effects in patients with pituitary adenomas. Front. Endocrinol. 11, 579606 (2020).","journal-title":"Front. Endocrinol."},{"key":"886_CR103","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000497331","volume":"109","author":"M Buchfelder","year":"2019","unstructured":"Buchfelder, M., Zhao, Y. & Schlaffer, S. M. Surgery for prolactinomas to date. Neuroendocrinology 109, 77\u201381 (2019).","journal-title":"Neuroendocrinology"},{"key":"886_CR104","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.3171\/2012.4.FOCUS1268","volume":"32","author":"G Lam","year":"2012","unstructured":"Lam, G., Mehta, V. & Zada, G. Spontaneous and medically induced cerebrospinal fluid leakage in the setting of pituitary adenomas: review of the literature. Neurosurg. Focus. 32, E2 (2012).","journal-title":"Neurosurg. Focus."},{"key":"886_CR105","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/cen.13940","volume":"90","author":"R Steeds","year":"2019","unstructured":"Steeds, R. et al. Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. Clin. Endocrinol. 90, 662\u2013669 (2019).","journal-title":"Clin. Endocrinol."},{"key":"886_CR106","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11102-019-00989-1","volume":"23","author":"P Souteiro","year":"2020","unstructured":"Souteiro, P., Belo, S. & Carvalho, D. Dopamine agonists in prolactinomas: when to withdraw? Pituitary 23, 38\u201344 (2020).","journal-title":"Pituitary"},{"key":"886_CR107","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1210\/js.2017-00038","volume":"1","author":"AC Paepegaey","year":"2017","unstructured":"Paepegaey, A. C. et al. Cabergoline tapering is almost always successful in patients with macroprolactinomas. J. Endocr. Soc. 1, 221\u2013230 (2017).","journal-title":"J. Endocr. Soc."},{"key":"886_CR108","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fendo.2015.00011","volume":"6","author":"L Vilar","year":"2015","unstructured":"Vilar, L. et al. Second attempt of cabergoline withdrawal in patients with prolactinomas after a failed first attempt: is it worthwhile? Front. Endocrinol. 6, 11 (2015).","journal-title":"Front. Endocrinol."},{"key":"886_CR109","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s11102-013-0525-x","volume":"17","author":"R Kwancharoen","year":"2014","unstructured":"Kwancharoen, R. et al. Second attempt to withdraw cabergoline in prolactinomas: a pilot study. Pituitary 17, 451\u2013456 (2014).","journal-title":"Pituitary"},{"key":"886_CR110","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11102-019-00998-0","volume":"23","author":"Y Greenman","year":"2020","unstructured":"Greenman, Y. Prolactinomas and menopause: any changes in management? Pituitary 23, 58\u201364 (2020).","journal-title":"Pituitary"},{"key":"886_CR111","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/er.2005-9998","volume":"27","author":"MP Gillam","year":"2006","unstructured":"Gillam, M. P., Molitch, M. E., Lombardi, G. & Colao, A. Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485\u2013534 (2006).","journal-title":"Endocr. Rev."},{"key":"886_CR112","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1530\/EJE-11-1000","volume":"166","author":"V Primeau","year":"2012","unstructured":"Primeau, V., Raftopoulos, C. & Maiter, D. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur. J. Endocrinol. 166, 779\u2013786 (2012).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR113","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1530\/EJE-07-0248","volume":"158","author":"J Kreutzer","year":"2008","unstructured":"Kreutzer, J. et al. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur. J. Endocrinol. 158, 11\u201318 (2008).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR114","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1530\/EJE-16-0087","volume":"175","author":"M Tampourlou","year":"2016","unstructured":"Tampourlou, M., Trifanescu, R., Paluzzi, A., Ahmed, S. K. & Karavitaki, N. Therapy of endocrine disease: surgery in microprolactinomas: effectiveness and risks based on contemporary literature. Eur. J. Endocrinol. 175, R89\u2013R96 (2016).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR115","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1530\/EJE-21-0293","volume":"185","author":"B Baussart","year":"2021","unstructured":"Baussart, B. et al. Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: a cohort study. Eur. J. Endocrinol. 185, 783\u2013791 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR116","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/neuros\/nyy385","volume":"85","author":"A Micko","year":"2019","unstructured":"Micko, A., Vila, G., Hoftberger, R., Knosp, E. & Wolfsberger, S. Endoscopic transsphenoidal surgery of microprolactinomas: a reappraisal of cure rate based on radiological criteria. Neurosurgery 85, 508\u2013515 (2019).","journal-title":"Neurosurgery"},{"key":"886_CR117","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fendo.2018.00636","volume":"9","author":"Q Ma","year":"2018","unstructured":"Ma, Q. et al. The chance of permanent cure for micro- and macroprolactinomas, medication or surgery? A systematic review and meta-analysis. Front. Endocrinol. 9, 636 (2018).","journal-title":"Front. Endocrinol."},{"key":"886_CR118","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/j.wneu.2021.07.035","volume":"154","author":"K Wright","year":"2021","unstructured":"Wright, K. et al. Determinants of surgical remission in prolactinomas: a systematic review and meta-analysis. World Neurosurg. 154, e349\u2013e369 (2021).","journal-title":"World Neurosurg."},{"key":"886_CR119","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1210\/jcem.87.7.8645","volume":"87","author":"M Losa","year":"2002","unstructured":"Losa, M., Mortini, P., Barzaghi, R., Gioia, L. & Giovanelli, M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J. Clin. Endocrinol. Metab. 87, 3180\u20133186 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR120","first-page":"1669","volume":"138","author":"RC Osorio","year":"2022","unstructured":"Osorio, R. C. et al. Correlation between tumor volume and serum prolactin and its effect on surgical outcomes in a cohort of 219 prolactinoma patients. J. Neurosurg.\u00a0138,\u00a01669\u20131679\u00a0(2022).","journal-title":"J. Neurosurg."},{"key":"886_CR121","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.clineuro.2013.02.016","volume":"115","author":"H Ikeda","year":"2013","unstructured":"Ikeda, H., Watanabe, K., Tominaga, T. & Yoshimoto, T. Transsphenoidal microsurgical results of female patients with prolactinomas. Clin. Neurol. Neurosurg. 115, 1621\u20131625 (2013).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"886_CR122","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3389\/fendo.2020.00439","volume":"11","author":"G Zielinski","year":"2020","unstructured":"Zielinski, G., Ozdarski, M., Maksymowicz, M., Szamotulska, K. & Witek, P. Prolactinomas: prognostic factors of early remission after transsphenoidal surgery. Front. Endocrinol. 11, 439 (2020).","journal-title":"Front. Endocrinol."},{"key":"886_CR123","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s11102-022-01221-3","volume":"25","author":"H Abou-Al-Shaar","year":"2022","unstructured":"Abou-Al-Shaar, H. et al. The role of endoscopic endonasal surgery in the management of prolactinomas based on their invasiveness into the cavernous sinus. Pituitary 25, 508\u2013519 (2022).","journal-title":"Pituitary"},{"key":"886_CR124","doi-asserted-by":"publisher","first-page":"e626","DOI":"10.1016\/j.wneu.2022.10.043","volume":"168","author":"BK Force","year":"2022","unstructured":"Force, B. K. et al. Endoscopic endonasal transsphenoidal surgery for patients with prolactinomas: indications and outcomes. World Neurosurg. 168, e626\u2013e635 (2022).","journal-title":"World Neurosurg."},{"key":"886_CR125","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.nec.2019.05.010","volume":"30","author":"DA Donoho","year":"2019","unstructured":"Donoho, D. A. & Laws, E. R. Jr. The role of surgery in the management of prolactinomas. Neurosurg. Clin. North Am. 30, 509\u2013514 (2019).","journal-title":"Neurosurg. Clin. North Am."},{"key":"886_CR126","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1530\/EJE-12-0236","volume":"167","author":"L Vroonen","year":"2012","unstructured":"Vroonen, L. et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur. J. Endocrinol. 167, 651\u2013662 (2012).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR127","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11102-010-0261-4","volume":"14","author":"M Menucci","year":"2011","unstructured":"Menucci, M., Quinones-Hinojosa, A., Burger, P. & Salvatori, R. Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary 14, 68\u201374 (2011).","journal-title":"Pituitary"},{"key":"886_CR128","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11102-018-0888-0","volume":"21","author":"A Nakhleh","year":"2018","unstructured":"Nakhleh, A. et al. Management of cystic prolactinomas: a review. Pituitary 21, 425\u2013430 (2018).","journal-title":"Pituitary"},{"key":"886_CR129","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1148\/radiology.170.1.2909102","volume":"170","author":"DM Yousem","year":"1989","unstructured":"Yousem, D. M., Arrington, J. A., Zinreich, S. J., Kumar, A. J. & Bryan, R. N. Pituitary adenomas: possible role of bromocriptine in intratumoral hemorrhage. Radiology 170, 239\u2013243 (1989).","journal-title":"Radiology"},{"key":"886_CR130","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s12020-021-02953-1","volume":"75","author":"C Hage","year":"2022","unstructured":"Hage, C. & Salvatori, R. Speed of response to dopaminergic agents in prolactinomas. Endocrine 75, 883\u2013888 (2022).","journal-title":"Endocrine"},{"key":"886_CR131","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1210\/jc.2016-2008","volume":"101","author":"A Faje","year":"2016","unstructured":"Faje, A. et al. Dopamine agonists can reduce cystic prolactinomas. J. Clin. Endocrinol. Metab. 101, 3709\u20133715 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR132","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/eje.0.1480325","volume":"148","author":"A Colao","year":"2003","unstructured":"Colao, A. et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur. J. Endocrinol. 148, 325\u2013331 (2003).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR133","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s12020-011-9462-5","volume":"39","author":"G Mazziotti","year":"2011","unstructured":"Mazziotti, G. et al. Vertebral fractures in males with prolactinoma. Endocrine 39, 288\u2013293 (2011).","journal-title":"Endocrine"},{"key":"886_CR134","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11102-010-0251-6","volume":"14","author":"I Shimon","year":"2011","unstructured":"Shimon, I., Benbassat, C., Tzvetov, G. & Grozinsky-Glasberg, S. Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression. Pituitary 14, 11\u201315 (2011).","journal-title":"Pituitary"},{"key":"886_CR135","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1007\/s12020-019-01962-5","volume":"65","author":"I Shimon","year":"2019","unstructured":"Shimon, I. et al. Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years. Endocrine 65, 656\u2013661 (2019).","journal-title":"Endocrine"},{"key":"886_CR136","first-page":"2102","volume":"82","author":"E Delgrange","year":"1997","unstructured":"Delgrange, E., Trouillas, J., Maiter, D., Donckier, J. & Tourniaire, J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J. Clin. Endocrinol. Metab. 82, 2102\u20132107 (1997).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR137","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000318494","volume":"38","author":"P Fainstein Day","year":"2010","unstructured":"Fainstein Day, P. et al. Gender differences in macroprolactinomas: study of clinical features, outcome of patients and Ki-67 expression in tumor tissue. Front. Horm. Res. 38, 50\u201358 (2010).","journal-title":"Front. Horm. Res."},{"key":"886_CR138","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S0090-3019(03)00012-0","volume":"59","author":"H Nishioka","year":"2003","unstructured":"Nishioka, H., Haraoka, J. & Akada, K. Growth potential of prolactinomas in men: is it really different from women?. Surg. Neurol. 59, 386\u2013390 (2003).","journal-title":"Surg. Neurol."},{"key":"886_CR139","first-page":"152","volume":"26","author":"B Schaller","year":"2005","unstructured":"Schaller, B. Gender-related differences in prolactinomas. A clinicopathological study. Neuro Endocrinol. Lett. 26, 152\u2013159 (2005).","journal-title":"Neuro Endocrinol. Lett."},{"key":"886_CR140","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1172\/JCI20401","volume":"112","author":"S Melmed","year":"2003","unstructured":"Melmed, S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J. Clin. Invest. 112, 1603\u20131618 (2003).","journal-title":"J. Clin. Invest."},{"key":"886_CR141","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11102-019-01000-7","volume":"23","author":"H Lasolle","year":"2020","unstructured":"Lasolle, H., Ilie, M. D. & Raverot, G. Aggressive prolactinomas: how to manage? Pituitary 23, 70\u201377 (2020).","journal-title":"Pituitary"},{"key":"886_CR142","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","volume":"17","author":"G Raverot","year":"2021","unstructured":"Raverot, G. et al. Aggressive pituitary tumours and pituitary carcinomas. Nat. Rev. Endocrinol. 17, 671\u2013684 (2021).","journal-title":"Nat. Rev. Endocrinol."},{"key":"886_CR143","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000495775","volume":"109","author":"D Maiter","year":"2019","unstructured":"Maiter, D. Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 109, 42\u201350 (2019).","journal-title":"Neuroendocrinology"},{"key":"886_CR144","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot, G. et al. European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur. J. Endocrinol. 178, G1\u2013G24 (2018).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR145","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1530\/EJE-17-0933","volume":"178","author":"A McCormack","year":"2018","unstructured":"McCormack, A. et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur. J. Endocrinol. 178, 265\u2013276 (2018).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR146","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11060-015-1991-y","volume":"126","author":"M Losa","year":"2016","unstructured":"Losa, M. et al. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. J. Neurooncol. 126, 519\u2013525 (2016).","journal-title":"J. Neurooncol."},{"key":"886_CR147","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1530\/EJE-16-0979","volume":"176","author":"H Lasolle","year":"2017","unstructured":"Lasolle, H. et al. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. Eur. J. Endocrinol. 176, 769\u2013777 (2017).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR148","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1210\/clinem\/dgz211","volume":"105","author":"U Elbelt","year":"2020","unstructured":"Elbelt, U. et al. Efficacy of temozolomide therapy in patients with aggressive pituitary adenomas and carcinomas \u2013 a German survey. J. Clin. Endocrinol. Metab. 105, e660\u2013e675 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR149","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/cen.14645","volume":"98","author":"B Goichot","year":"2023","unstructured":"Goichot, B. et al. Should pituitary carcinoma be treated using a NET-like approach? A case of complete remission of a metastatic malignant prolactinoma with multimodal therapy including immunotherapy. Clin. Endocrinol. 98, 633\u2013637 (2023).","journal-title":"Clin. Endocrinol."},{"key":"886_CR150","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1530\/EJE-22-0647","volume":"187","author":"MD Ilie","year":"2022","unstructured":"Ilie, M. D. et al. Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study. Eur. J. Endocrinol. 187, 685\u2013696 (2022).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR151","doi-asserted-by":"publisher","first-page":"101712","DOI":"10.1016\/j.beem.2022.101712","volume":"36","author":"G Raverot","year":"2022","unstructured":"Raverot, G. & Ilie, M. D. Immunotherapy in pituitary carcinomas and aggressive pituitary tumors. Best. Pract. Res. Clin. Endocrinol. Metab. 36, 101712 (2022).","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"886_CR152","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1210\/jc.2018-02461","volume":"104","author":"D Zhang","year":"2019","unstructured":"Zhang, D. et al. Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas. J. Clin. Endocrinol. Metab. 104, 1929\u20131936 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR153","doi-asserted-by":"publisher","first-page":"e917","DOI":"10.1210\/clinem\/dgaa805","volume":"106","author":"O Cooper","year":"2021","unstructured":"Cooper, O. et al. EGFR\/ErbB2-targeting lapatinib therapy for aggressive prolactinomas. J. Clin. Endocrinol. Metab. 106, e917\u2013e925 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR154","volume":"15","author":"T Bazuhair","year":"2023","unstructured":"Bazuhair, T., Aleid, B. & Almalki, M. Effect of tamoxifen on the management of dopamine agonist-resistant prolactinomas: a systematic review. Cureus 15, e35171 (2023).","journal-title":"Cureus"},{"key":"886_CR155","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11154-020-09554-9","volume":"21","author":"S Petersenn","year":"2020","unstructured":"Petersenn, S. & Heaney, A. P. Targeted systemic and peptide radio-ligand therapy for aggressive pituitary tumors and carcinomas. Rev. Endocr. Metab. Disord. 21, 277\u2013286 (2020).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"886_CR156","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","volume":"20","author":"FF Casanueva","year":"2017","unstructured":"Casanueva, F. F. et al. Criteria for the definition of pituitary tumor centers of excellence (PTCOE): a Pituitary Society statement. Pituitary 20, 489\u2013498 (2017).","journal-title":"Pituitary"},{"key":"886_CR157","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s12020-019-02054-0","volume":"66","author":"HP Zhong","year":"2019","unstructured":"Zhong, H. P. et al. Multidisciplinary team efforts improve the surgical outcomes of sellar region lesions during pregnancy. Endocrine 66, 477\u2013484 (2019).","journal-title":"Endocrine"},{"key":"886_CR158","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s11102-019-01008-z","volume":"23","author":"BG Sant\u2019 Anna","year":"2020","unstructured":"Sant\u2019 Anna, B. G. et al. A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas. Pituitary 23, 120\u2013128 (2020).","journal-title":"Pituitary"},{"key":"886_CR159","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1530\/EJE-21-0075","volume":"185","author":"I Martinez de LaPiscina","year":"2021","unstructured":"Martinez de LaPiscina, I. et al. Clinical and genetic characteristics in patients under 30 years with sporadic pituitary adenomas. Eur. J. Endocrinol. 185, 485\u2013496 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR160","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11154-019-09534-8","volume":"21","author":"C Tatsi","year":"2020","unstructured":"Tatsi, C. & Stratakis, C. A. Aggressive pituitary tumors in the young and elderly. Rev. Endocr. Metab. Disord. 21, 213\u2013223 (2020).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"886_CR161","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000486280","volume":"89","author":"T Breil","year":"2018","unstructured":"Breil, T. et al. Clinical features and response to treatment of prolactinomas in children and adolescents: a retrospective single-centre analysis and review of the literature. Horm. Res. Paediatr. 89, 157\u2013165 (2018).","journal-title":"Horm. Res. Paediatr."},{"key":"886_CR162","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1515\/jpem-2018-0475","volume":"32","author":"CM Brichta","year":"2019","unstructured":"Brichta, C. M., Wurm, M., Krebs, A., Schwab, K. O. & van der Werf-Grohmann, N. Start low, go slowly \u2013 mental abnormalities in young prolactinoma patients under cabergoline therapy. J. Pediatr. Endocrinol. Metab. 32, 969\u2013977 (2019).","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"886_CR163","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00431-017-3042-5","volume":"177","author":"A Hoffmann","year":"2018","unstructured":"Hoffmann, A., Adelmann, S., Lohle, K., Claviez, A. & Muller, H. L. Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis. Eur. J. Pediatr. 177, 125\u2013132 (2018).","journal-title":"Eur. J. Pediatr."},{"key":"886_CR164","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s11102-018-0900-8","volume":"21","author":"E Culpin","year":"2018","unstructured":"Culpin, E. et al. Pituitary tumour apoplexy within prolactinomas in children: a more aggressive condition? Pituitary 21, 474\u2013479 (2018).","journal-title":"Pituitary"},{"key":"886_CR165","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.wneu.2014.12.026","volume":"83","author":"PP Jankowski","year":"2015","unstructured":"Jankowski, P. P. et al. Pituitary tumor apoplexy in adolescents. World Neurosurg. 83, 644\u2013651 (2015).","journal-title":"World Neurosurg."},{"key":"886_CR166","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/cen.14477","volume":"95","author":"A McCormack","year":"2021","unstructured":"McCormack, A. Childhood-onset prolactinomas \u2013 should earlier surgery be considered? Clin. Endocrinol. 95, 571\u2013573 (2021).","journal-title":"Clin. Endocrinol."},{"key":"886_CR167","doi-asserted-by":"publisher","first-page":"101711","DOI":"10.1016\/j.beem.2022.101711","volume":"36","author":"P Chanson","year":"2022","unstructured":"Chanson, P. Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists. Best. Pract. Res. Clin. Endocrinol. Metab. 36, 101711 (2022).","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"886_CR168","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1080\/13651501.2018.1425459","volume":"22","author":"FD Alosaimi","year":"2018","unstructured":"Alosaimi, F. D. et al. Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications. Int. J. Psychiatry Clin. Pract. 22, 274\u2013281 (2018).","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"886_CR169","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","volume":"64","author":"PM Haddad","year":"2004","unstructured":"Haddad, P. M. & Wieck, A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64, 2291\u20132314 (2004).","journal-title":"Drugs"},{"key":"886_CR170","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.genhosppsych.2007.11.002","volume":"30","author":"SC Chang","year":"2008","unstructured":"Chang, S. C., Chen, C. H. & Lu, M. L. Cabergoline-induced psychotic exacerbation in schizophrenic patients. Gen. Hosp. Psychiatry 30, 378\u2013380 (2008).","journal-title":"Gen. Hosp. Psychiatry"},{"key":"886_CR171","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1530\/EJE-20-0125","volume":"183","author":"L Allard","year":"2020","unstructured":"Allard, L. et al. Efficacy and safety of dopamine agonists in patients treated with antipsychotics and presenting a macroprolactinoma. Eur. J. Endocrinol. 183, 221\u2013231 (2020).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR172","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s40263-021-00812-1","volume":"35","author":"FMC Besag","year":"2021","unstructured":"Besag, F. M. C., Vasey, M. J. & Salim, I. Is adjunct aripiprazole effective in treating hyperprolactinemia induced by psychotropic medication? A narrative review. CNS Drugs 35, 507\u2013526 (2021).","journal-title":"CNS Drugs"},{"key":"886_CR173","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3109\/09513599709152546","volume":"11","author":"LA Balint-Peric","year":"1997","unstructured":"Balint-Peric, L. A. & Prelevic, G. M. Changes in prolactin levels with the menopause: the effects of estrogen\/androgen and calcitonin treatment. Gynecol. Endocrinol. 11, 275\u2013280 (1997).","journal-title":"Gynecol. Endocrinol."},{"key":"886_CR174","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1046\/j.1365-2265.2001.01190.x","volume":"54","author":"S Karunakaran","year":"2001","unstructured":"Karunakaran, S., Page, R. C. & Wass, J. A. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin. Endocrinol. 54, 295\u2013300 (2001).","journal-title":"Clin. Endocrinol."},{"key":"886_CR175","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/cen.13765","volume":"89","author":"S Santharam","year":"2018","unstructured":"Santharam, S. et al. Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal. Clin. Endocrinol. 89, 346\u2013353 (2018).","journal-title":"Clin. Endocrinol."},{"key":"886_CR176","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s12672-019-00363-4","volume":"10","author":"R Indirli","year":"2019","unstructured":"Indirli, R. et al. Cabergoline withdrawal before and after menopause: outcomes in microprolactinomas. Horm. Cancer 10, 120\u2013127 (2019).","journal-title":"Horm. Cancer"},{"key":"886_CR177","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0015-0282(97)81368-4","volume":"67","author":"Y Maor","year":"1997","unstructured":"Maor, Y. & Berezin, M. Hyperprolactinemia in postmenopausal women. Fertil. Steril. 67, 693\u2013696 (1997).","journal-title":"Fertil. Steril."},{"key":"886_CR178","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12020-014-0259-1","volume":"47","author":"I Shimon","year":"2014","unstructured":"Shimon, I. et al. Women with prolactinomas presented at the postmenopausal period. Endocrine 47, 889\u2013894 (2014).","journal-title":"Endocrine"},{"key":"886_CR179","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/cen.13399","volume":"87","author":"S Santharam","year":"2017","unstructured":"Santharam, S. et al. Prolactinomas diagnosed in the postmenopausal period: clinical phenotype and outcomes. Clin. Endocrinol. 87, 508\u2013514 (2017).","journal-title":"Clin. Endocrinol."},{"key":"886_CR180","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1530\/EJE-15-0282","volume":"173","author":"OM Dekkers","year":"2015","unstructured":"Dekkers, O. M. et al. Breast cancer risk in hyperprolactinemia: a population-based cohort study and meta-analysis of the literature. Eur. J. Endocrinol. 173, 269\u2013273 (2015).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR181","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1530\/EC-17-0171","volume":"6","author":"E Soto-Pedre","year":"2017","unstructured":"Soto-Pedre, E., Newey, P. J., Bevan, J. S. & Leese, G. P. Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS study. Endocr. Connect. 6, 580\u2013588 (2017).","journal-title":"Endocr. Connect."},{"key":"886_CR182","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1210\/jc.2017-01658","volume":"102","author":"WC Hembree","year":"2017","unstructured":"Hembree, W. C. et al. Endocrine treatment of gender-dysphoric\/gender-incongruent persons: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 102, 3869\u20133903 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR183","doi-asserted-by":"publisher","DOI":"10.1111\/and.12666","volume":"49","author":"NM Nota","year":"2017","unstructured":"Nota, N. M. et al. Prolactin levels during short- and long-term cross-sex hormone treatment: an observational study in transgender persons. Andrologia 49, e12666 (2017).","journal-title":"Andrologia"},{"key":"886_CR184","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1089\/lgbt.2016.0190","volume":"4","author":"J Defreyne","year":"2017","unstructured":"Defreyne, J. et al. Transient elevated serum prolactin in trans women is caused by cyproterone acetate treatment. LGBT Health 4, 328\u2013336 (2017).","journal-title":"LGBT Health"},{"key":"886_CR185","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s12020-020-02563-3","volume":"72","author":"LM Raven","year":"2021","unstructured":"Raven, L. M., Guttman-Jones, M. & Muir, C. A. Hyperprolactinemia and association with prolactinoma in transwomen receiving gender affirming hormone treatment. Endocrine 72, 524\u2013528 (2021).","journal-title":"Endocrine"},{"key":"886_CR186","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1365-2265.1978.tb02206.x","volume":"9","author":"EA Cowden","year":"1978","unstructured":"Cowden, E. A., Ratcliffe, W. A., Ratcliffe, J. G., Dobbie, J. W. & Kennedy, A. C. Hyperprolactinaemia in renal disease. Clin. Endocrinol. 9, 241\u2013248 (1978).","journal-title":"Clin. Endocrinol."},{"key":"886_CR187","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0272-6386(85)80181-5","volume":"6","author":"SH Hou","year":"1985","unstructured":"Hou, S. H., Grossman, S. & Molitch, M. E. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am. J. Kidney Dis. 6, 245\u2013249 (1985).","journal-title":"Am. J. Kidney Dis."},{"key":"886_CR188","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1210\/jcem-62-2-352","volume":"62","author":"D Rodriguez-Puyol","year":"1986","unstructured":"Rodriguez-Puyol, D. et al. Molecular heterogeneity of circulating prolactin in chronic uremic men and renal transplant recipients. J. Clin. Endocrinol. Metab. 62, 352\u2013356 (1986).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"886_CR189","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1530\/eje.0.1310489","volume":"131","author":"JD Veldhuis","year":"1994","unstructured":"Veldhuis, J. D., Iranmanesh, A., Wilkowski, M. J. & Samojlik, E. Neuroendocrine alterations in the somatotropic and lactotropic axes in uremic men. Eur. J. Endocrinol. 131, 489\u2013498 (1994).","journal-title":"Eur. J. Endocrinol."},{"key":"886_CR190","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/hdi.12489","volume":"21","author":"JC Lo","year":"2017","unstructured":"Lo, J. C. et al. Hyperprolactinemia in end-stage renal disease and effects of frequent hemodialysis. Hemodial. Int. 21, 190\u2013196 (2017).","journal-title":"Hemodial. Int."},{"key":"886_CR191","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/00006842-198306000-00008","volume":"45","author":"R Weizman","year":"1983","unstructured":"Weizman, R. et al. Sexual dysfunction associated with hyperprolactinemia in males and females undergoing hemodialysis. Psychosom. Med. 45, 259\u2013269 (1983).","journal-title":"Psychosom. Med."},{"key":"886_CR192","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/039139888901200204","volume":"12","author":"RM Schaefer","year":"1989","unstructured":"Schaefer, R. M., Kokot, F., Kuerner, B., Zech, M. & Heidland, A. Normalization of serum prolactin levels in hemodialysis patients on recombinant human erythropoietin. Int. J. Artif. Organs 12, 445\u2013449 (1989).","journal-title":"Int. J. Artif. Organs"}],"updated-by":[{"DOI":"10.1038\/s41574-023-00916-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000}}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-023-00886-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-023-00886-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-023-00886-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T04:04:25Z","timestamp":1710993865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-023-00886-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":192,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["886"],"URL":"https:\/\/doi.org\/10.1038\/s41574-023-00886-5","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,5]]},"assertion":[{"value":"27 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41574-023-00916-2","URL":"https:\/\/doi.org\/10.1038\/s41574-023-00916-2","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}